Publication date: 06/09/2017
MDxHealth SA (Euronext: MDXH.BR) today announced the appointment of Michael K. Brawer, MD as Chief Medical Officer in a series of executive hires to prepare the Company for growth in the second half of the year and beyond.
Dr. Brawer is an accomplished urologist and former professor of urology and pathology, with over 25 years of industry experience leading clinical affairs for urology-focused diagnostic and pharmaceutical companies.
Most recently, Dr. Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialization of their prognostic prostate cancer assay. Previously, Dr. Brawer held senior leadership positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. Prior to his corporate career, Dr. Brawer was a practicing urologist and the Director of the Northwest Prostate Institute for almost a decade, after holding teaching positions in pathology and urology at the University of Washington and University of Arizona.
Over the first seven months of 2017, in addition to bringing on Dr. Brawer, MDxHealth has expanded its executive function with the appointment of Jean-Marc Roelandt as Chief Financial Officer, Shalon Roth as Executive Vice President of Corporate Communications & Public Affairs and Paul Marr as Executive Vice President of Sales for North America.
"MDxHealth has made industry-changing advancements to improve prostate cancer diagnosis with its portfolio of tests, and commands a leading position in molecular diagnostic testing for urology," stated Michael Brawer MD, CMO, MDxHealth. "I am thrilled to work with this highly experienced executive management and clinical affairs team to help the Company build upon its proven success in the market."
"We are excited to welcome such an accomplished medical professional to our Executive Leadership Team and are confident that Dr. Brawer's extensive industry experience will help further advance our clinical and commercial strategy," commented Dr. Jan Groen, CEO, MDxHealth. "Dr. Brawer's arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase."
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.